August 19, 2015 / 10:36 PM / 4 years ago

Depomed rejects Horizon Pharma's offer for the third time

(Reuters) - Depomed Inc DEPO.O rejected Horizon Pharma Plc’s (HZNP.O) takeover bid for the third time, reiterating that the offer undervalued the company.

Depomed said Horizon Pharma’s latest all-stock bid had a current value of $30 per share, or about $1.81 billion, lower than Horizon’s previous offer of $33.

Horizon Pharma said last Thursday it would offer 0.95 Horizon Pharma shares for every Depomed share. It had also said it could alternatively offer Depomed shareholders $32.50 in cash and stock.

Horizon Pharma first approached Depomed in May and went hostile with its offer in July after being rejected. Depomed adopted a poison pill to stave off the bid.

Up to Wednesday’s close of $31.27, Horizon Pharma’s stock had fallen about 4 percent since its initial offer on May 27th.

Reporting by Anet Josline Pinto in Bengaluru; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below